In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemphire Therapeutics Inc.

www.gemphire.com

Latest From Gemphire Therapeutics Inc.

Venture Funding Deals: Korean D&D Raises $137.1m For Subsidiary Model

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in July and August.
Deals Financing

Novo Carves Deeper Niche Into CV Market With Staten Dyslipidemia Investment

Novo Nordisk is making good on its strategy to prioritize the cardiovascular sector. Its latest deal sees the Danish pharma invest in Staten Biotechnology’s hypertriglyceridemia asset, with potential to acquire the company.

Cardiovascular Deals

Gemphire Reels From Two R&D Blows

A series of setbacks for gemcabene has left the Livonia, MI-based company reeling, but management remains committed to its lead product.

Clinical Trials Research & Development

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Hepatic (Liver)
  • Alias(es)
  • Michigan Life Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gemphire Therapeutics Inc.
  • Senior Management
  • Steve Gullans, PhD, CEO
    Charles Bisgaier, PhD, CSO
    Seth Reno, Chief Commercial Officer
  • Contact Info
  • Gemphire Therapeutics Inc.
    Phone: (734) 245-1700
    17199 N. Laurel Park Dr.,
    Ste. 401
    Livonia, MI 48152
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register